|
||
(Commission File No.)
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
||
|
||
|
||
|
Not Applicable
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
|
|
Myovant Sciences Ltd.
|
|||
|
|
|||
Date:
|
May 26, 2021
|
By:
|
/s/ Matthew Lang
|
|
|
Name:
|
Matthew Lang
|
||
|
|
Title:
|
General Counsel and Corporate Secretary
|
Document and Entity Information |
May 26, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | May 26, 2021 |
Entity Registrant Name | Myovant Sciences Ltd. |
Entity Incorporation, State or Country Code | D0 |
Entity File Number | 001-37929 |
Entity Tax Identification Number | 98-1343578 |
Entity Address, Address Line One | Suite 1, 3rd Floor |
Entity Address, Address Line Two | 11-12 St. James’s Square |
Entity Address, City or Town | London |
Entity Address, Country | GB |
Entity Address, Postal Zip Code | SW1Y 4LB |
Country Region | 44 |
City Area Code | 207 |
Local Phone Number | 400 3351 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001679082 |
Title of 12(b) Security | Common Shares, par value $0.000017727 per share |
Trading Symbol | MYOV |
Security Exchange Name | NYSE |